2024

  • Bajaj PS, et al. Burden of AL Amyloidosis and Its Association With Cardiac Involvement: Initial Results From a Patient-Reported Outcome Survey. Presented at 21st International Myeloma Society Annual Meeting and Exposition; September 25-28, 2024. Rio De Janeiro, Brazil. View abstract | View presentation
  • Palladini G, et al. The Mechanism of Action, Pharmacological Characteristics, and Clinical Utility of the Amyloid Depleter Birtamimab for the Potential Treatment of AL Amyloidosis. Leuk Lymphoma. 2024;1–11. doi:10.1080/10428194.2024.2337803. Online ahead of print. PubMed
  • D'Souza A, et al. Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial. Presented at the XIX International Symposium on Amyloidosis 2024; May 26-30, 2024. Rochester, MN. View abstract | View presentation
  • Bajaj P, et al. Increasing Prevalence and Incidence of AL Amyloidosis Among Older Adults in the US. Presented at the XIX International Symposium on Amyloidosis 2024; May 26-30, 2024. Rochester, MN. View abstract | View presentation

2023

  • Gertz MA, et al. Pooled Analysis of Safety From Birtamimab Phase 1-3 Studies in Patients With Light Chain (AL) Amyloidosis. Presented at 65th ASH Annual Meeting and Exposition; December 9-12, 2023. San Diego, CA. View abstract
  • D’Souza A, et al. Determinants of Higher Cost and Inpatient Hospitalization Among Patients With AL Amyloidosis. Presented at ISPOR EU 2023; November 12-15, 2023. Copenhagen, Denmark. 
    View abstract | View presentation
  • D’Souza A, et al. Clinical and Economic Burden of Patients With and Without Light Chain (AL) Amyloidosis: A Matched Control Analysis of Insurance Claims. Presented at AMCP Nexus 2023; October 16-19, 2023. Orlando, FL. View abstract | View presentation
  • Rizio AA, et al. Association Between Hematologic Response and Change in Health-Related Quality of Life among Patients With Light Chain (AL) Amyloidosis. Patient Rel Outcome Meas. 2023;14:297-304. PubMed
  • Gertz MA, et al. Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis. Clinicoecon Outcomes Res. 2023;15:673-680. PubMed
  • Gertz MA, et al. Birtamimab Plus Standard of Care in Light Chain Amyloidosis: The Phase 3 Randomized Placebo-Controlled VITAL Trial. Blood. 2023;142:1208–1218. PubMed
  • Rizio AA, et al. Health-Related Quality of Life Instruments For Clinical Trials in AL Amyloidosis: Report From the Amyloidosis Forum HRQOL Working Group. Patient Relat Outcome Meas. 2023;14:153-169. PubMed
  • Quock TP, et al. In-Hospital Mortality in Amyloid Light Chain Amyloidosis: Analysis of the Premier Healthcare Database. J Comp Eff Res. 2023;12:e220185. PubMed

2022

  • D’Souza A, et al. Diagnostic Amyloid Light Chain Amyloidosis Hospitalizations Associated With High Acuity and Cost: Analysis of the Premier Healthcare Database. J Comp Eff Res. 2022;11:1225-1230. PubMed
  • Gertz MA, et al. Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis in the Phase 3 VITAL Study Consistent After Adjustment for Key Baseline Variables. Presented at 64th ASH Annual Meeting and Exposition; December 10-13, 2022. New Orleans, LA. View abstract | View presentation
  • Gertz MA, et al. Healthcare Utilization Among Patients With Advanced Systemic Light Chain Amyloidosis. Blood. 2022;140:13129-13131. View abstract
  • Gertz MA, et al. Birtamimab in Patients With Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory AFFIRM-AL Phase 2 Study. Presented at International Society on Amyloidosis; September 4-8, 2022; Heidelberg, Germany. View abstract | View presentation
  • Quock TP, et al. Diagnostic Hospitalization and Associated Costs in Patients With Amyloid Light-Chain Amyloidosis. Presented at International Society on Amyloidosis; September 4-8, 2022. Heidelberg, DE. View abstract | View presentation

2021

  • Gertz MA, et al. Birtamimab in Patients With Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory AFFIRM-AL Phase 3 Study Design. Presented at 63rd ASH Annual Meeting and Exposition; December 10-14, 2021; Atalanta, GA and Virtual. View abstract | View presentation
  • Rizio AA, et al. Work Outcomes Among Patients With Light Chain (AL) Amyloidosis: Findings From Three Patient Cohorts. Patient Relat Outcome Meas. 2021;12:339-347. PubMed

2019

  • Gertz MA, et al. Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients With Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Presented at 61st ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, FL. View abstract | View presentation
  • Quock TP, et al. Untangling the Clinical and Economic Burden of Hospitalization for Cardiac Amyloidosis in the United States. Clinicoecon Outcomes Res. 2019;11:431-439. PubMed

2018

  • Quock TP, et al. Healthcare Resource Utilization and Costs in Amyloid Light Chain Amyloidosis: A Real-World Study Using US Claims Data. J Comp Eff Res. 2018;7:549-559. PubMed
  • Quock TP, et al. Epidemiology of AL Amyloidosis: A Real-World Study Using US Claims Data. Blood Adv. 2018;2:1046-1053. PubMed
  • McCausland KL, et al. Light Chain (AL) Amyloidosis: The Journey to Diagnosis. Patient. 2018;11:207-216. PubMed

2016

  • Gertz MA, et al. First-in-Human Phase l/ll Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016;34:1097-1103. PubMed
  • Renz M, et al. 2A4 Binds Soluble and Insoluble Light Chain Aggregates From AL Amyloidosis Patients and Promotes Clearance of Amyloid Deposits by Phagocytosis. Amyloid. 2016;23:168-177. PubMed

2012

  • Wall JS, et al. AL Amyloid Imaging and Therapy With a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils. PLoS One. 2012;7:e52686. PubMed

2011

  • Wall JS, et al. Generation and Characterization of Anti-AA Amyloid-Specific Monoclonal Antibodies. Front Immunol. 2011;2:32. PubMed